(CercleFinance.com) – Bristol Myers Squibb publishes adjusted EPS (non-GAAP) for the last three months of 2023, down 7% to $1.70, for revenues up 1% to just under 11 .5 billion, still penalized by lower sales of Revlimid.
Over the entire past financial year, it recorded adjusted EPS down 2% to $7.51, at the bottom of its target range from three months ago (7.50 to 7. 65 dollars), with a decline of 2% in its revenues, in accordance with its forecasts.
For the year 2024, the pharmaceutical company indicates that it anticipates adjusted EPS (excluding the impact of current transactions) of between $7.10 and $7.40, as well as revenue growth in the low single-digit range.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
